Design Therapeutics, Inc.
DSGN
$4.72
-$0.24-4.84%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 2.37% | 647.86% | |||
| Gross Profit | -2.37% | -647.86% | |||
| SG&A Expenses | 3.82% | -3.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.76% | 8.00% | |||
| Operating Income | -2.76% | -8.00% | |||
| Income Before Tax | -4.69% | -10.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.69% | -10.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.69% | -10.57% | |||
| EBIT | -2.76% | -8.00% | |||
| EBITDA | -2.81% | -8.06% | |||
| EPS Basic | -4.56% | -10.46% | |||
| Normalized Basic EPS | -4.59% | -10.44% | |||
| EPS Diluted | -4.56% | -10.46% | |||
| Normalized Diluted EPS | -4.59% | -10.44% | |||
| Average Basic Shares Outstanding | 0.11% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.11% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
